Logo

Vertex Reports Positive Results of Triple Combination Therapy in P-III Studies for Cystic Fibrosis

Share this

Vertex Reports Positive Results of Triple Combination Therapy in P-III Studies for Cystic Fibrosis

Shots:

  • The two P-III studies involve assessing of VX-445 + tezacaftor + ivacaftor vs triple PBO & PBO + tezacaftor + ivacaftor in 405 & 108 patients with one F508del mutation + F/MF & two F508del mutations respectively
  • The two P-III studies resulted in meeting its 1EP as improvement in lung function (ppFEV1) (13.8% & 10%) respectively and is safe- effective and tolerable
  • Vertex plans to submit NDA to US FDA in Q3’19 and MAA to EU in Q4’19 for VX-659 or VX-445 triple combination therapy based on clinical studies

Ref: Vertex | Image: Vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions